FAM54B Inhibitors
FAM54B inhibitors comprise a diverse array of compounds that reduce the activity of FAM54B by altering specific cellular pathways. For instance, Taxol hampers cell division by stabilizing microtubules, which could lead to a reduction in FAM54B activity by curtailing the cellular proliferation necessary for its function. Staurosporine, a broad-spectrum kinase inhibitor, predominantly targets PKC, potentially decreasing FAM54B activity if it is influenced by PKC-mediated signaling. Rapamycin, by binding to mTORC1, inhibits a central pathway regulating cell growth, which may result in diminished FAM54B activity if FAM54B is implicated in mTORC1-linked processes. Sorafenib's inhibition of various tyrosine kinases and the Raf family could similarly result in the attenuation of FAM54B activity by influencing signaling pathways that regulate FAM54B-related cellular functions.
The activity of FAM54B is further influenced by chemicals that affect gene expression and protein stability. Trichostatin A, by inhibiting histone deacetylases, alters gene expression profiles, which could lead to a decreased FAM54B activity through modifications in the expression of genes interacting with or regulating FAM54B. Bortezomib, by inhibiting the proteasome, could stabilize proteins involved in cell cycle regulation, potentially affecting FAM54B if it is associated with such regulatory mechanisms. Autophagy inhibitors like Chloroquine, along with PI3K pathway inhibitors LY 294002 and Wortmannin, may also contribute to the reduced activity of FAM54B by altering autophagy processes and PI3K/Akt signaling, where FAM54B may be implicated. Additionally, U0126, through its selective inhibition of MEK1/2, indirectly affects the MAPK/ERK pathway, which could lead to a decrease in FAM54B activity if it is associated with MAPK/ERK signaling. Collectively, these FAM54B inhibitors, through targeted effects on distinct cellular pathways, contribute to the downregulation of FAM54B activity without directly modifying its expression or function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $40.00 $73.00 $217.00 $242.00 $724.00 $1196.00 | 39 | |
Taxol stabilizes microtubules and prevents their depolymerization, which can interfere with cell division. By disrupting the microtubule dynamics necessary for mitosis, it indirectly leads to a decrease in FAM54B activity due to decreased cell proliferation where FAM54B might be involved. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent protein kinase C (PKC) inhibitor. By inhibiting PKC, it could diminish signaling pathways that involve PKC-dependent phosphorylation, potentially reducing FAM54B activity if FAM54B is a substrate or associated with PKC signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically binds to mTOR complex 1 (mTORC1) and inhibits its activity. Since mTOR signaling is crucial for cell growth and proliferation, rapamycin may lead to a decrease in FAM54B activity by suppressing the pathways in which FAM54B is functionally involved. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib targets multiple tyrosine protein kinases, such as VEGFR and PDGFR, and also the Raf kinases. By inhibiting these kinases, it may reduce signaling that could affect cellular processes where FAM54B plays a role, thus indirectly diminishing FAM54B activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that prevents the degradation of proteins involved in cell cycle regulation. By stabilizing these proteins, it could indirectly affect the cell cycle and potentially reduce FAM54B activity if FAM54B is involved in such regulatory processes. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. It alters chromatin structure and affects gene expression. This compound can indirectly diminish FAM54B activity by affecting the expression of genes and proteins that interact with or regulate FAM54B. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective inhibitor of c-Jun N-terminal kinase (JNK). It diminishes JNK signaling, which could indirectly affect FAM54B activity by altering the expression of genes or interacting proteins that are part of JNK signaling pathways. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide modulates the expression of multiple cytokines and has anti-inflammatory properties. By altering cytokine profiles, it could indirectly affect signaling pathways where FAM54B might play a role, thus diminishing FAM54B activity. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine is known for its ability to inhibit autophagy by preventing lysosome acidification. By inhibiting autophagy, it could lead to a decrease in FAM54B activity if FAM54B is involved in this cellular process or is regulated by autophagic degradation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a PI3K inhibitor that diminishes PI3K/Akt signaling pathway activity. By inhibiting this pathway, it could indirectly lead to a reduction in FAM54B activity, if FAM54B is linked to PI3K/Akt signaling. | ||||||